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Abstract
The p38 MAPK signaling pathway plays a pivotal role in inflammation. Targeting p38 MAPK may be a potential strategy for
the treatment of inflammatory diseases. In the present study, we show that a novel chromone derivative, DCO-6,
significantly reduced lipopolysaccharide (LPS)-induced production of nitric oxide, IL-1b and IL-6, decreased the levels of
iNOS, IL-1b and IL-6 mRNA expression in both RAW264.7 cells and mouse primary peritoneal macrophages, and inhibited
LPS-induced activation of p38 MAPK but not of JNK, ERK. Moreover, DCO-6 specifically inhibited TLR4-dependent p38
activation without directly inhibiting its kinase activity. LPS-induced production of intracellular reactive oxygen species
(ROS) was remarkably impaired by DCO-6, which disrupted the formation of the TRAF6-ASK1 complex. Administering DCO-6
significantly protected mice from LPS-induced septic shock in parallel with the inhibition of p38 activation and ROS
production. Our results indicate that DCO-6 showed anti-inflammatory properties through inhibition of ROS-dependent
activation of TRAF6-ASK1-p38 pathway. Blockade of the upstream events required for p38 MAPK action by DCO-6 may
provide a new therapeutic option in the treatment of inflammatory diseases.
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Introduction
In mammals, the innate immune system is the first line of host
defense against invading pathogens and is mediated by innate
immune cells including macrophages [1]. Macrophages are critical
effector cells contributing to the innate immune response against
infection, as they are the most efficient pathogen scavengers and
the predominant source of pro-inflammatory cytokines such as IL-
1b, IL-6 and TNF-a, which are pivotal to promote inflammation
at the site of infection and fight against pathogens [2,3]. However,
excess or inappropriate production of pro-inflammatory cytokines
has serious consequences including tissue damage and septic shock
[4,5]. Therefore, inhibiting the synthesis or release of these
cytokines and other cellular mediators emerges as a potential
therapeutic approach for septic shock-like diseases associated with
inappropriately amplified inflammatory responses.
The Toll-like receptor (TLR) family is one of the best-
characterized pattern recognition receptor (PRR) families and is
responsible for sensing invading pathogens. Recognition of
bacterial components such as lipopolysaccharide (LPS) by TLRs
results in the recruitment of multiple cytoplasmic signaling
molecules involving MyD88, TRAF6, TIRAP and IRAK, which
eventually activate downstream signaling components such as
SAPK/JNK, p38 and NF-kB [6,7,8]. As an E3 ubiquitin ligase,
TRAF6 interacts with various protein kinases including IRAK,
SRC, and apoptosis signal-regulating kinase 1 (ASK1) and
provides a link between distinct signaling pathways [9,10,11].
ASK1, a MAP kinase kinase kinase, plays an essential role in
cytokine- and stress-induced apoptosis in mammalian cells by
activating the MAP kinase kinase 4 (MKK4) and MKK3, which in
turn lead to the activation of JNK and p38 pathways [12,13,14].
Recent studies have shown that ASK1 formed a complex with
TRAF6 in response to LPS, and this complex formation and
subsequent activation of p38 pathway required LPS-induced
production of reactive oxygen species (ROS) [9,10,11].
Chromones have been extensively studied as bioactive
compounds. They possess remarkable biological activities, in-
cluding potent anti-inflammatory actions [15]. Our previous
results revealed the diphenolic chromone derivatives as a new
class of anti-inflammatory leads which showed potent inhibitory
activity on nitric oxide (NO) production [16]. In this study, we
investigated anti-inflammatory property of (E)-5,7-dihydroxy-3-
(3-oxo-3-phenylprop-1-en-1-yl)-4H-chromen-4-one (DCO-6),
a novel diphenolic chromone derivative. The results indicate
that DCO-6 significantly reduced LPS-induced production of
NO, IL-1b and IL-6 and decreased the levels of iNOS, IL-1b
and IL-6 mRNA expression in macrophages. Moreover, LPS-
induced activation of p38 MAPK was remarkably impaired by
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15DCO-6 due to its inhibitory effects on the production of ROS
and formation of TRAF6-ASK1 complex. In addition, DCO-6
alleviated LPS-induced mortality in murine model of septic
shock, suggesting that DCO-6 may have use as a treatment for
inflammatory diseases.
Results
DCO-6 inhibits LPS-induced NO, IL-1b and IL-6
Production in RAW264.7 and Peritoneal Macrophages
The synthesis of (E)-5,7-dihydroxy-3-(3-oxo-3-phenylprop-1-en-
1-yl)-4H-chromen-4- one (DCO-6) is outlined in supplementary
material S1, and the
1H NMR spectrum of DCO-6 was shown in
Fig. S1. DCO-6 at concentrations ranging from 1 to 30 mM failed
to affect cell viability of both mouse RAW264.7 macrophages and
primary mouse peritoneal macrophages (Fig. 1B and Fig. S2).
Thus, up to 30 mM of DCO-6 was used in the following in vitro
experiments.
To assess the effects of DCO-6 on LPS-induced production of
cellular mediator in RAW264.7 and peritoneal macrophages, cell
culture medium was harvested. Measuring nitrite as the index of
NO production by the Griess method, we found that LPS
treatment for 24 h resulted in a large amount of NO release in
macrophages (Fig. 2A). Co-incubation of DCO-6 with LPS
inhibited the formation of NO in a concentration-dependent
manner. In addition, LPS-induced production of IL-1b and IL-6
was significantly reduced in macrophages treated with DCO-6
(Fig. 2A). When RNA was isolated and quantitative real-time
PCR was performed to examine the effects of DCO-6 on gene
expression, Co-incubation of DCO-6 with LPS also decreased the
levels of iNOS, IL-1b and IL-6 mRNA expression (Fig. 2B),
suggesting that NO, IL-1b and IL-6 reduction by DCO-6 may be
related to transcriptional inhibition. However, neither TNF-
a release nor mRNA induction was altered by DCO-6 at
concentration of up to 30 mM (Fig. S3).
DCO-6 Inhibits the Activation of p38 MAPK as well as NF-
kB Signaling Induced by LPS in RAW264.7 Cells
In LPS signaling, activation of mitogen-activated protein
kinases (MAPKs) and transcription factor NF-kB play essential
roles in transcriptional induction of those genes involved in
inflammation, such as iNOS, COX-2, TNF-a, IL-1b and IL-6
[17]. Here, we assessed the effects of DCO-6 on activation of
MAPKs in RAW264.7 upon response to LPS. As shown in
Fig. 3A, DCO-6 inhibited p38 MAPK phosphorylation induced
by LPS in a concentration-dependent manner without any effect
on total p38 MAPK expression. In contrast, DCO-6 did not
affect phosphorylation of JNK, ERK induced by LPS. In spite
of the failure in inhibition of phosphorylation of IKKa/b,
DCO-6 slightly reduced phosphorylation of IkBa (Fig. 3B).
Moreover, the nuclear localization of p65 subunit of NF-kB was
inhibited by DCO-6, in line with the blockade of DNA binding
activity of p65 in LPS-stimulated RAW264.7 cells (Fig. 3C and
3D).
DCO-6 Inhibits p38 MAPK Activation Dependent on TLR
Ligands in RAW264.7 Cells
Next we used LPS (a ligand for TLR4), poly (I:C) (a synthetic
double-stranded RNA and a ligand for TLR3) or unmethylated
CpG (a ligand for TLR9) to stimulate RAW264.7 cells. As
shown in Fig. 4A, p38 MAPK phosphorylation was substantially
induced upon any stimuli. However, DCO-6 failed to reduce
p38 phosphorylation induced by poly (I:C) or CpG, suggesting
that DCO-6 specifically inhibited TLR4-dependent p38 activa-
tion. In an in vitro kinase assay to determine the direct effect of
DCO-6 on the p38 MAPK, we found that, unlike p38 MAPK
inhibitor SB203580, which can inhibit p38 MAPK at 10 mM,
DCO-6 did not affect the kinase activity of p38 MAPK (Fig. 4B
and Fig. S4).
DCO-6 Inhibits the Production of Intracellular ROS and
Formation of the TRAF6-ASK1 Complex in
RAW264.7 Cells
Given that the generation of ROS is required for TLR4-
dependent activation of p38 but not JNK [18], we examined
whether DCO-6 inhibited LPS-induced phosphorylation of p38
by reducing ROS production. After treatment for 6 h, LPS, but
not poly (I:C) or CpG, resulted in a large amount of ROS
production in RAW264.7 cells (Fig. 5A). DCO-6 inhibited LPS-
induced ROS production in a concentration-dependent manner
(Fig. 5B) and 30 mM of DCO-6 showed the inhibitory activity
Figure 1. The effect of DCO-6 on cell viability of murine macrophages. (A) The chemical structure of DCO-6. (B) RAW264.7 cells or peritoneal
macrophages from BALB/c mice were treated with various concentrations of DCO-6. After 24 h of incubation, LDH in the culture supernatant was
tested. The absorbance value at 420 nm was measured by a microplate reader. The percentage of LDH released from the cells was determined using
the formula: % release = LDH activity in supernatant/(LDH activity in supernatant + LDH activity in cell lysate). Data are shown as means 6 S.D. of
three independent experiments. *P,0.05 vs medium control.
doi:10.1371/journal.pone.0037168.g001
Chromone Exhibits Anti-Inflammatory Property
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 8 | e37168comparable to 1 mM of the antioxidant N-acetyl-L-cystein
(NAC). In addition, 1 mM of H2O2 in RAW264.7 cells induced
p38 phosphorylation and Co-incubation of DCO-6 with H2O2
inhibited the phosphorylation of p38 in a concentration-de-
pendent manner (Fig. 5C).
It is known that ROS mediates LPS-induced p38 activation by
inducing the formation of the TRAF6-ASK1 complex [11]. Then,
we examined the effects of DCO-6 on interactions between
TRAF6 and ASK. As shown in Fig. 5D, TRAF6 did not
coimmunoprecipitate ASK1 in the absence of LPS stimulation,
whereas there was definite interaction between TRAF6 and ASK1
in RAW264.7 cells upon LPS stimulation. DCO-6 at 30 mM had
no effect on the protein expression of TRAF6 and ASK1, but
completely disrupted their interaction.
DCO-6 Protects Mice from LPS-induced Septic Shock with
a Significant Inhibition of p38 Activation
To assess the protective effects of DCO-6 against LPS-induced
lethal shock in vivo, BALB/c mice were intraperitoneally admin-
istered LPS (10 mg/kg) and DCO-6 (10 and 20 mg/kg).
Cumulative proportions of mice surviving after lethal dose of
LPS were shown in Fig. 6A. Single administration of DCO-6
improved survival in a dose-dependent manner. At 48 h after LPS
injection, survival rate of DCO-6 treated mice (20 mg/kg) was
50% while none of untreated mice were alive. Moreover, LPS-
induced IL-6 and IL-1b were significantly reduced in serum of
DCO-6-treated groups (Fig. 6B). In addition, inhibition of p38
activation and ROS production was also observed in peritoneal
macrophages from septic mice treated with DCO-6 (Fig. 6C and
6D).
Discussion
This study examined the anti-inflammatory effect of the
synthetic chromone derivative DCO-6 and its underlying mech-
anism. Our results suggest that the inhibition of TRAF6-ASK1-
p38 signaling pathway by DCO-6 contributes to its anti-
inflammatory action in reducing LPS-induced production of
NO, IL-1b and IL-6 in macrophages and protecting against
LPS-induced septic shock in mice. In contrast, DCO-6 did not
affect the other two MAPK signaling cascades, ERK and JNK,
elicited by LPS.
LPS-induced activation of p38 MAPK in macrophages has been
widely demonstrated to correspond to the in vitro and in vivo effects
of LPS on positive regulation of a variety of genes involved in
inflammation. p38 MAPK signaling is implicated in LPS-induced
transcriptional activation of pro-inflammatory genes, such as
iNOS, COX-2, IL-1b and IL-6 [19,20,21,22]. DCO-6 concen-
tration-dependently inhibited LPS-induced p38 phosphorylation,
an index of p38 MAPK activation. Accordingly, DCO-6 sub-
stantially decreased the levels of iNOS, IL-1b and IL-6 mRNA
expression in macrophages. However, TNF-a production and
mRNA induction was unaffected by DCO-6 in vitro. Multiple
MAPK pathways activated by LPS are involved in the regulation
of TNF-a expression [23]. It is possible that the p38 inhibition
alone can not lead to significant attenuation of TNF-a transcrip-
tional activity. Consistent with this finding, the selective p38
inhibitor SB203580 shows ineffectiveness on TNF-a promoter
activity [24].
Despite the inhibition of p38 MAPK signaling induced by
LPS, DCO-6 is not a direct inhibitor of p38 MAPK’s catalytic
function as evidenced by the in vitro kinase assay, where DCO-6
Figure 2. Inhibition of LPS-induced NO, IL-1b and IL-6 production by DCO-6 in murine macrophages. RAW264.7 cells or peritoneal
macrophages from BALB/c mice were treated with various concentrations of DCO-6 in the absence or presence of LPS. (A) The levels of NO, IL-1b and
IL-6 in the cell culture medium were determined 24 h after LPS stimulation as described in Methods. (B) The levels of iNOS, IL-1b and IL-6 mRNA were
determined by real-time quantitative PCR 8 h after LPS stimulation. b-actin was used as an invariant control. Data are shown as means 6 S.D. of three
independent experiments. *P,0.05 vs LPS control.
doi:10.1371/journal.pone.0037168.g002
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stimulation by different TLR ligands, DCO-6 specifically
inhibited TLR4-dependent p38 activation, suggesting that
DCO-6 might block upstream events required for LPS-induced
p38 MAPK activation. Indeed, we found that LPS, but not poly
(I:C) or CpG, resulted in a large amount of ROS production.
And DCO-6 significantly inhibited ROS production in macro-
phages stimulated by LPS. Accumulating evidence has shown
ROS are not only injurious by-products of cellular metabolism
but also essential participants in cell signaling and regulation
Figure 3. Effects of DCO-6 on the LPS-induced activation of MAPKs and NF-kB in RAW264.7 cells. Cells were treated with various
concentrations of DCO-6 in the absence or presence of LPS for 6 h. (A–B) The protein levels of total and phosphorylated p38, JNK, ERK and IKKa, IKKb,
IkBa were determined at least three times, and the representative data are shown. (C) Cytoplasmic and nuclear proteins were extracted and assayed
by immunoblotting analysis. Expressions of b-actin and LaminB1 were shown as loading controls. Bands from (A–C) were analyzed by densitometry.
Quantitative data are shown. *P,0.05 vs LPS control. (D) Nuclear proteins were extracted and assayed by EMSA. A 75-fold excess of unlabelled
oligonucleotide probe and mutant probe were used as controls.
doi:10.1371/journal.pone.0037168.g003
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DCO-6 in the absence or presence of indicated TLR ligands for 6 h. Whole cell lysates were prepared for Western blotting analysis. The protein levels
of total and phosphorylated p38 were determined at least three times, and the representative data are shown. (B) Cells were stimulated by 500 ng/ml
LPS for 6 h and the protein was collected. Phosphorylated p38 MAPK was immunoprecipitated. The immune complexes were used for testing the
effects of DCO-6 and SB203580 on kinase activities. Representative data are shown. Bands from (A–B) were analyzed by densitometry. Quantitative
data are shown. *P,0.05 vs control.
doi:10.1371/journal.pone.0037168.g004
Figure 5. Effects of DCO-6 on the production of intracellular ROS and the formation of TRAF6-ASK1 complex in RAW264.7 cells. (A)
Cells were incubated in the absence or presence of indicated TLR ligands for 6 h. Intracellular ROS production was detected by DCF fluorescence
using flow cytometry. (B) Cells were treated with various concentrations of DCO-6 in the absence or presence of LPS. Intracellular ROS production was
detected as mentioned above. Data are shown as means 6 S.D. of three independent experiments. *P,0.05 vs LPS control. (C) Cells were treated
with various concentrations of DCO-6 in the absence or presence of H2O2 for 6 h. Whole cell lysates were prepared for Western blotting analysis. The
protein levels of total and phosphorylated p38 were determined at least three times, and representative data are shown. (D) The interaction between
TRAF6 and ASK1 was measured by coimmunoprecipitation assay. Representative data are shown.
doi:10.1371/journal.pone.0037168.g005
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formation of a complex between TRAF6 and the redox-sensitive
ASK1, which in turn triggers p38 activation [11,13]. In current
study, DCO-6 completely disrupted the interaction between
TRAF6 and ASK1 in RAW264.7 cells upon LPS stimulation,
although the expression of TRAF6 and ASK1 protein was
unaffected. These results indicate that DCO-6 may inhibit ROS-
dependent activation of TRAF6 -ASK1-p38 pathway which
leads to the production of inflammatory factors.
p38 MAPK’s role in the regulation of inflammatory cytokines
and enzymes responsible for inflammation–like COX2, iNOS and
MMPs–makes it an attractive drug target [28]. Several small
molecular inhibitors targeting p38 have been developed and
evaluated in animal models of inflammatory diseases [29,30]. In
this study, treatment with DCO-6 alleviated LPS-induced septic
shock in mice and inhibited p38 activation in vivo. The anti-
inflammatory potential of an oral p38 MAPK inhibitor was also
evaluated in human endotoxemia [31]. Despite the strong
rationale for MAPK inhibitors in human disease, direct proof of
concept in the clinic has yet to be demonstrated, with most
compounds demonstrating dose-limiting adverse effects [32].
Identification of new classes of compounds with greater specificity
or a deeper knowledge of the other targets in p38 MAPK pathway
could overcome these side-effects. Selective inhibition of more
upstream events involved in p38 MAPK signaling may be a feasible
strategy.
Although chromones and their structural analogues are known
to play an important protective role against oxidation processes,
many chromone-based compounds have demonstrated more
fascinating properties. For example, it is reported that cromogly-
cate, a chromone complex, increases survival during an experi-
mental model of sepsis by inhibiting HMGB1 release [33]. Unlike
DCO-6, cromoglycate showed no effect on the LPS-induced p38
phosphorylation (Fig. S5). 30 mM of DCO-6 slightly, but
significantly, reduced DNP-induced b-hexosaminidase release in
Rat basophilic leukemia RBL-2H3 cells (Fig. S6). The results
indicate that DCO-6 might have inhibitory effect on anaphylactic
response through a different pathway from mast cell stabilizer
cromoglycate. Recent study has shown that some chromone
derivatives were synthesized and evaluated as p38 MAP kinase
inhibitors [34]. However, the novel synthetic compound DCO-6
did not affect the kinase activity of p38 MAPK. DCO-6 showed
low cytotoxicity and strong anti-inflammatory activity. Blocking
the upstream events required for p38 MAPK action by DCO-6
may provide a new therapeutic option in the treatment of human
inflammatory diseases.
Figure 6. Protective effect of DCO-6 against LPS-induced septic shock in mice. BALB/c mice were administered LPS (10 mg/kg) and DCO-6
(10 or 20 mg/kg) or vehicle (olive oil) intraperitoneally. (A) Survival rate. (B) Serum cytokine levels of IL-1b and IL-6 were measured by ELISA 3 h after
LPS injection. Data are shown as means 6 S.D. of three independent experiments. n =10. *P,0.05 vs model control. (C) Peritoneal macrophages
were isolated from the mice 3 h after LPS injection. Whole cell lysates were prepared, and the protein levels of total and phosphorylated p38 was
detected by Western blotting analysis. Traces shown are representative of three independent experiments. Bands from (C) were analyzed by
densitometry. Quantitative data are shown. *P,0.05 vs model control. (D) Peritoneal macrophages were isolated from the mice 3 h after LPS
injection and incubated with DCFH-DA. DCF fluorescence distribution was detected by flow cytrometry. Data were analyzed by Cell Quest software.
*P,0.05 vs model control.
doi:10.1371/journal.pone.0037168.g006
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Cells and Reagents
Murine RAW264.7 macrophages, obtained from the American
Type Culture Collection (Rockville, MD), were cultured in
DMEM (Invitrogen Corp., Carlsbad, CA) containing 5% fetal
bovine serum (GIBCO, Grand Island, NY), 100 U/ml penicillin,
and 100 mg/ml streptomycin in 5% CO2 at 37uC. Peritoneal
macrophages elicited by thioglycollate broth (Sigma, St Louis,
MO) were harvested by lavage of the peritoneal cavity. LPS from
Escherichia coli (0111:B4), poly (I:C) and unmethylated CpG were
purchased from Sigma, Invitrogen and Invitrogen, respectively.
All other chemicals were obtained from Sigma.
Mice
Male BALB/c, 6–8 weeks of age, were purchased from
Experimental Animal Center of Jiangsu Province (Jiangsu, China).
They were maintained with free access to pellet food and water in
plastic cages at 2162uC and kept on a 12 h light/dark cycle.
Animal welfare and experimental procedures were carried out in
accordance with the Guide for the Care and Use of Laboratory
Animals (Ministry of Science and Technology of China, 2006) and
the related ethical regulations of our university. All the animal
experiments were approved by Nanjing University Animal Care
and Use Committee (NJU-ACUC) and made to minimize
suffering and to reduce the number of animals used.
Measurement of Cytotoxicity, Nitrite and Cytokines
Cells (5610
4 per well) were cultured in a 96-well plate, and
treated with various concentrations of DCO-6. After 24 h of
incubation, LDH in the culture supernatant and in cell lysate were
tested by using the CytoTox 96H Non-Radioactive Cytotoxicity
Assay (Promega Corp., Shanghai). The percentage of LDH
released from the cells was determined using the formula: %
release = LDH activity in supernatant/(LDH activity in
supernatant + LDH activity in cell lysate). For nitrite measure-
ment, cells were treated with various concentrations of DCO-6 in
the absence or presence of LPS (500 ng/ml) for 24 h, and then
nitrite in the culture supernatant was measured by Griess reagent
(Promega). And the nitrite concentration was calculated by using
standard solution of sodium nitrite in the culture medium. For
cytokine assay, IL-1b and IL-6 production were measured using
ELISA kits from R&D systems (Minneapolis, MN) according to
the manufacturer’s instructions.
Real-time PCR
Real-time PCR was performed as described previously [35].
Briefly, RNA samples were treated by DNase and subjected to
quantitative PCR, which was performed with the ABI Prism 7000
sequence detection system (Applied Biosystems, Foster City, CA)
using SYBR Green I dye (Biotium, Inc.), and threshold cycle
numbers were obtained using ABI Prism 7000 SDS software
version 1.0. Conditions for amplification were 1 cycle of 94uC for
5 min followed by 40 cycles of 94uC for 30 s, 58uC for 30 s, and
72uC for 45 s. The primer sequences used in this study were as
follows: iNOS forward, 59-CAACATCAGGTCGGCCATCACT-
39; iNOS reverse, 59-ACCAGAGGCAGCACATCAA AGC-39;
IL-1b forward, 59-CTTCAGGCAGGCAGTATC ACTC-39; IL-
1b reverse, 59-TGCAGTTGTCTAATGGGAACGT-39; IL-6
forward, 59-ACAACCACGGCCTTCC CTAC-39; IL-6 reverse,
59-TCTCATTTCCACGATT- TCCCAG-39; b-actin: forward,
59-TGCTGTCCCTGTATGCCTCT-39; b-actin reverse, 59-
TTTGATGTCACGCACGATTT-39.
Western Blotting Analysis
Western blotting was performed as described previously [36].
Cells were collected and lysed in the lysis buffer containing Triton
X-100. After 10,000 g centrifugation for 10 min, the protein
content of the supernatant was determined by a BCA
TM protein
assay Kit (Pierce, Rochford, IL). The protein lysates were
separated by 10% SDS-PAGE and subsequently electrotransferred
onto a polyvinylidene diuoride membrane (Millipore Corp.,
Bedford, MA). The membrane was blocked with 5% nonfat milk
for 1 h at room temperature. The blocked membrane was
incubated with the indicated antibodies. Protein bands were
visualized using Western blotting detection system according to the
manufacturer’s instructions.
For extraction of nucleoprotein, cells were collected and lysed in
the lysis buffer (10 mM Hepes pH 7.9, 1.5 mM MgCl2,1 0m M
KCl, 0.5 mM DTT, 2% NP-40, 1 mM PMSF) for 20 min, and
the lysis buffer was centrifugated at 280 g for 10 minutes. the
protein content of the supernatant was collected as cytoplasmic
protein. Precipitation were washed twice and lysed in the lysis
buffer containing Triton X-100 as nucleoprotein.
p38 MAP Kinase Activity Assay
Cells were stimulated by 500 ng/ml LPS for 6 h and the protein
was collected. p38 MAP Kinase activity was detected by p38 MAP
Kinase Assay Kit (Cell Signaling Technology). Briefly, endogenous
kinases were immuno- precipitated from cell lysates using
phospho-p38 (Thr180/Tyr182) antibody bound to protein-A
agarose. The beads were washed twice with lysis buffer and twice
with kinase buffer (25 mM Hepes pH 7.4, 25 mM MgCl2,2 5m M
b-glycerophosphate, 100 mM sodium orthovanadate, 2 mM
DTT). The immunoprecipitates were incubated with DCO-6
(30 mM) or SB203580 (10 mM) for 10 min before the addition of
kinase buffer containing ATP and ATF2 fusion protein as
a substrate for p38. After further incubation for 30 min at 30uC,
the phosphorylated ATF2 products were resolved by SDS-PAGE
and analyzed by immunoblot according to the manufacturer’s
instructions.
Electrophoretic Mobility Shift assay (EMSA) Assay
EMSA was performed as described previously [37]. Briey,
nucleoprotein (5 mg) was incubated in a 20 ml reaction volume
(10 mM Tris–HCl, pH 7.8, 1 mM EDTA, 100 mM KCl, 5 mM
MgCl2,1mg/ml poly dI.dC) for 20 min at 37uC and then loaded
onto a 6% nondenaturing polyacrylamide gel. After cross-link
transferred DNA to membrane, the bands were detected by
chemiluminesecence. A 75-fold excess of unlabelled oligonucleo-
tide probe and mutant probe were added in binding reaction to
prove if the shifted bands binds specifically to NF-kB oligonucleo-
tides. For supershift assays, 5 mg of rabbit anti-p65 polyclonal
antibody (Cell Signaling Technology, Danvers, MA.) was in-
cubated with the protein extract for 30 min prior to binding
reaction.
Measurement of Intracellular ROS
Cells (2610
5 per well) were cultured in a 6-well plate, and
treated with various concentrations of DCO-6 in the presence of
different TLR ligands for 6 h. Then the cells were harvested and
incubated with 2,7-dichlorofluorescein diacetate (DCFH-DA,
Invitrogen) at 37uC for 20 min and washed twice with cold PBS.
DCF fluorescence distribution was detected by flow cytrometry on
a FACScan (Becton Dickinson) at an excitation wavelength of
488 nm and an emission wavelength of 525 nm. Data were
analyzed by Cell Quest software (Molecular Devices Corporation).
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For coimmunoprecipitation, cells (1610
8) were lysed in lysis
buffer containing Triton X-100 and cell lysates were immunopre-
cipitated with polyclonal mouse antibody to TRAF6 or control
mouse immunoglobulin G with protein A/G–Sepharose. The
beads were washed, separated by SDS-PAGE and analyzed by
immunoblot with antibodies to ASK1 and TRAF6 (Santa Cruz).
Protein bands were visualized using Western blotting detection
system.
LPS-induced Septic Shock in Mice
BALB/c mice were administered LPS at 10 mg/kg intraperi-
toneally and survival was monitored for 48 h (n =10 per group).
DCO-6 (10 or 20 mg/kg) or vehicle (olive oil) was administered
intraperitoneally at the day of LPS injection. In some experiments,
blood samples were collected 3 h post LPS, and serum levels of IL-
1b and IL-6 were measured using ELISA kit from R&D systems
according to the manufacturer’s instructions.
Statistical Analysis
All data represent as means 6 S.D. of three independent
experiments. Statistical analyses were performed using one-way
analysis of variance (ANOVA), followed by Student two-tailed t
test. Mortality differences between groups were evaluated by the
Kaplan-Meier method. P ,0.05 was considered significant.
Supporting Information
Figure S1 The
1H NMR spectrum of DCO-6.
(TIF)
Figure S2 The effect of DCO-6 on cell viability of
murine macrophages. RAW264.7 cells or peritoneal macro-
phages from BALB/c mice were treated with various concentra-
tions of DCO-6. After 24 h of incubation, the cell viability was
assessed by MTT assay. Data are shown as means 6 S.D. of three
independent experiments.
*P,0.05 vs medium control.
(TIF)
Figure S3 The effect of DCO-6 on TNF-a production in
murine macrophages. RAW264.7 cells or peritoneal macro-
phages from BALB/c mice were treated with various concentra-
tions of DCO-6 in the absence or presence of LPS. (A) The levels
of TNF-a in the cell culture medium were determined 24 h after
LPS stimulation. (B) The levels of TNF-a mRNA were determined
by real-time quantitative PCR 8 h after LPS stimulation. b-actin
was used as an invariant control. Data are shown as means 6 S.D.
of three independent experiments.
(TIF)
Figure S4 Effects of DCO-6 on LPS-induced p38 MAPK
activation in RAW264.7 cells. Cells were treated with DCO-6
and SB203580 in the absence or presence of LPS for 6 h.
Endogenous kinases were immunoprecipitated from cell lysates
using phospho-p38 (Thr180/Tyr182) antibody bound to protein-
A agarose. The phosphorylated p-p38 products were analyzed by
immunoblot. Representative data are shown.
(TIF)
Figure S5 Effects of cromoglycate on p38 MAPK activa-
tion induced by LPS in RAW264.7 cells. Cells were treated
with various concentrations of cromoglycate in the absence or
presence of LPS for 6 h. Whole cell lysates were prepared for
Western blotting analysis. The phosphorylated p38 level was
analyzed by immunoblot.
(TIF)
Figure S6 DCO-6 inhibited DNP-BSA-induced b-hexos-
aminidase release in RBL-2H3 cells. As described in
supplementary material S1, cells were seeded in 96-well plates
(3610
4 cells/well) with or without 0.45 mg/ml anti-dinitrophenyl
(DNP) IgE. After overnight incubation, the sensitized cells were
treated with the indicated concentration of DCO-6 for 24 h.
DNP-BSA (1 mg/ml) were added for 30 min and b-hexosamini-
dase release levels were detected.
*P,0.05 vs DNP-BSA control.
(TIF)
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